Overview

Diagnostic Performance and Safety of Pegsitacianine for the Detection of Cancer in Patients With Unknown Primary Head and Neck Cancer

Status:
Not yet recruiting

Trial end date:
2027-12-31

Target enrollment:

Participant gender:

Summary

This is a non-randomized, open-label, single-center, safety and imaging feasibility study of Pegsitacianine, an intraoperative fluorescence imaging agent.

Phase:

Phase 2

Details

Lead Sponsor:

University of Texas Southwestern Medical Center